Carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone as maintenance therapy after autologous stem-cell transplantation in patients with multiple myeloma (ATLAS): interim analysis of a randomised, open-label, phase 3 trial.

ABSTRACT:

SUBMITTER: Dytfeld D 

PROVIDER: S-EPMC10337122 | biostudies-literature | 2023 Feb

REPOSITORIES: biostudies-literature